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tion, but it likely that this side effect will signiﬁcantly affect the clinical 
use of this very promising class of antineoplastic drugs.
The ubiquitin-proteasome pathway is the major proteolytic system in 
the cytosol and nucleus of all eukariotic cells and a target for anticancer 
chemotherapy. Although it is in no way clear how and where bortezo-
mib (the ﬁrst-in-class proteasome inhibitor) administration can affect 
the peripheral nervous system, at least one-third of the patients under 
treatment have had evidence of clinically-relevant sensory peripheral 
neuropathy. Treatment withdrawal resulted in clinical improvement, 
but the low number of patients studied makes it impossible to draw any 
ﬁrm conclusion about this. 
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Treatment-related pneumonitis continues to be a problem in patients 
receiving thoracic radiotherapy (RT), occurring (≥Grade 3) in 13-16% 
of patients treated with the 3-dimensional RT alone or with concurrent 
chemotherapy. Treatment-related pneumonitis can result in death in 2-
3% of patients. Pneumonitis usually does not affect the delivery of RT, 
being a subacute or late toxicity, but may result in death or signiﬁcant 
disability.
The incidence of treatment-related pneumonitis reported in the RTOG 
experience of four clinical trials of concurrent chemoradiotherapy in 
patients with inoperable NSCLC (Werner-Wasik et al, 2002; Bradley et 
al, 2005) was as follows: Grade 1, 24%; Grade 2, 22%; Grade 3, 16%; 
Grade 4, 2% and Grade 5, 2%. Interestingly, a similar incidence of 
pneumonitis was observed in the RT dose -escalation study of radio-
therapy alone, without chemotherapy (13-16% Grade≥3; Bradley et 
al, 2005). In a recently reported experience from a Phase III SWOG 
(Southwest Oncology Group) 0023 study of concurrent chemoradio-
therapy, docetaxel consolidation and placebo vs. geﬁtinib consolidation 
in 620 NSCLC patients (Gaspar et al, 2005), severe (Grade≥3) pneu-
monitis was observed in 9% of all patients and in 16% of the patient 
subset whose RT records were reviewed in detail. 
Symptomatic pneumonitis classically develops between 1-6 months 
from completion of thoracic RT, although new cases of pneumonitis 
were observed in the RTOG database up to 18 months. It manifests as 
cough, dyspnea and rarely, fever. In patients with chronic lung disease, 
the symptoms of pneumonitis may be difﬁcult to distinguish form the 
underlying lung disease. Treatment-related pneumonitis remains there-
fore a diagnosis of exclusion.
The most current grading system for pneumonitis is that provided by 
the United States NCI (National Cancer Institute) Common Termi-
nology Criteria for Adverse Events v3.0 (CTCAE), where Grade 3 
pneumonitis is deﬁned as “Symptomatic, interfering with Activities 
of Daily Living; oxygen indicated”, and Grade 4 as “Life-threatening; 
ventilatory support indicated”. 
The treatment of established symptomatic treatment-related pneumo-
nitis remains supportive, consisting of prednisone, usually initiated at 
a daily dose of 40-60 mg followed by a very slow taper over several 
weeks. Antibiotics, bronchodilators, oxygen and ventilatory support are 
used as needed.
Several predictive factors are thought to be associated with pneumo-
nitis, including irradiated lung volume, RT dose, RT fraction size and 
frequency, pre-RT lung reserve and interaction with chemotherapy. 
Among the dosimetric tools, the “V
dose
”, or volume of the lung receiv-
ing a certain minimum RT dose (for example, “V
20
”, or volume of the 
lung receiving 20 Gy or more), is a simple and practical tool applicable 
to daily radiation planning. Values of V
20
<25% are rarely (<10%) as-
sociated with radiation pneumonitis (Graham M et al, 1999), although 
such a low V
20
 can be accomplished only for small lung tumors. Most 
cooperative groups (RTOG, SWOG) allow a V
20
 of <35% as a fairly 
safe and yet feasible value for most deﬁnitively treated lung cancers. 
Mean Lung Dose (MLD) is another dosimetric indicator of the risk of 
pneumonitis, which seems to correlate very closely with the V
20
 (Can-
dish et al, 2005). Of note, the validity of the V
20
 is preserved only for 
standard RT fractions. For larger fraction sizes V
20
 values may need to 
be lower (for example, V
20
 becomes V
18
 for a fraction size of 2.5 Gy). 
Hyperfractionated regimens, such as CHART (Continuous Hyperfrac-
tionated Radiation Therapy) may require yet a different V
dose
 as a pre-
dictor of RP. In patients after pneumonectomy, the value of V20 may 
need to be at least halved to predict safe delivery of postoperative RT. 
Despite those limitations, the V
20
 constraint remains a useful guideline 
for patients receiving standard -fractionated RT. Although dosimetric 
parameters are associated with RP risk, they do not have high predic-
tive power (PPV, or Positive Predictive Power of 18-38%; Rodrigues 
et al, 2004). Therefore, biologic models are needed to improve the 
accuracy of prediction.
There are no universally accepted serum markers predicting radiation 
pneumonitis, although TGF-beta (transforming growth factor-beta) has 
been suggested by some investigators to be valuable, particularly when 
combined with a dosimetric factor, such as the V
20
 (Fu 2001). 
So far no measures have been approved as providing effective pre-
vention of pneumonitis. Amifostine administered during concurrent 
chemoradiotherapy in locally advanced NSCLC was reported to lower 
the risk of high-grade pneumonitis in one institutional randomized trial 
(Komaki R et al, 2002), but this observation was not conﬁrmed in the 
large RTOG 98-01 Phase III randomized study (Movsas et al 2005). 
Other potential lung protectors (keratinocyte growth factors, superoxide 
dismutase) will need to be further tested in randomized trials in patients 
with lung cancer to prove their value. 
In summary, RP continues to challenge patients with lung cancer and 
the clinicians taking care of them. More basic and clinical research is 
necessary to accurately predict and treat this complication of therapy of 
thoracic malignancies.
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Pain is not universal in lung cancer, but is common, is present in about 
25% of patients at presentation with an increase to about 50% later. 
Most reviews report that it is often inadequately relieved when severe. 
Pain syndromes found in lung cancer and mesothelioma can be catego-
rised as follows:
1. Sub (retro) - sternal visceral pain 
2. Unilateral visceral pain
3. Chest wall pain (including brachial plexopathy)
4. Post-Thoracotomy 
5. Pain from metastases (especially bone, liver, brain)
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Cancer pain of any cause is divided into pain deriving from nocicep-
tors, either visceral or somatic; and neuropathic. Neuropathic pain 
originates both from inﬂammation and destruction of peripheral nerves 
(for example a chest wall tumour), and/or from aberrant neurological 
somato-sensory processing in CNS neurones. It has three principal fea-
tures: dysasthesia (a burning quality); paroxysmal or lancinating pains 
either spontaneous or evoked by touch; an expansion of the area where 
pain is sensed (hyper-algesia); and allodynia - abherrant pain reception 
in response to a gentle stimulus such as stroking the skin. Abnormal 
autonomic nerve function may be a component.
General Principles 
Management of pain in cancer needs:
1. A diagnosis; (the usual error in lung cancer is not to consider every 
pain as due to the cancer unless proved otherwise. 
2. A systematic assessment, eg type? Site and radiation? Intensity? 
Time pattern, ie constant or varying? Worsening and relieving factors 
(eg movement, coughing) and associated symptoms (eg vomiting).
3. Careful review of any co-morbidity (eg osteoarthritis, rheumatoid 
arthritis; reﬂux oeseophagitis).
Principles of pain management include:
1. Treatment is adjusted for the pain type and intensity.
2. Use oral drugs whenever possible
3. Regular analgesics - not as required
4. Frequent physician or specialist nurse review, eg every 24 to 72 hours
5. Rapid specialist review if not controlled (eg for nerve blocks)
6. Adequate attention to side effects of analgesics and co-analgesics 
(eg constipation, nausea, urinary retention, gastric irritation)
Analgesics
For many years the WHO 3-step pain control ladder has been the basis 
of management. 1-paracetamol + NSAID’s. 2-Codeine, Dextroproxy-
phene + step 1. 3-morphine or equivalent strong opioid + step 1. 
Despite the advent of newer opioid analgesics eg Fentanyl and 
Oxycodone and new formulations (eg slow release hydromorphone), 
morphine is still recommended by international review bodies as the 
opioid of ﬁrst choice. This is because of its wide availability, different 
formulations, and non-inferiority in comparisons of efﬁcacy.
The different analgesic modes of action and side effect proﬁles of 
the other strong opiods may however be an advantage for individual 
patients. Hydromorphone is less sedative; Fentanyl is available trans-
dermally for chronic use and mucosally for breakthrough pain. It also 
causes somewhat less constipation and drowsiness than morphine. It 
is perhaps a little better too in renal failure. Methadone is more potent, 
and in experienced hands may be useful in difﬁcult neuropathic pain. 
Switching at equipotent doses from one opiod to another may be useful 
in resistant pain, but there is usually no indication to use more than one 
opioid at the same time. 
Breakthrough Pain
Breakthrough pain is of 3 sorts. First, it is part of the dose ranging 
phase of opioid treatment; second, it is common as a between-dose pain 
when the usual recommendation is to offer 25-50% of the standard 4 
hourly dose for management; and third, it is incident pain where it is 
sudden and transient (for example from bone metastases), where oral 
morphine is often too slow for relief. Alternatives in this difﬁcult situ-
ation include transmucosal fentanyl (effective in about 15 minutes), as 
well as mechanical aids and occupational therapy advice. 
Neuropathic Pain
Neuropathic pain is a well known component of superior sulcus tu-
mours, peripheral lung cancer with chest wall invasion, mesothelioma, 
and most persistent post thoracotomy pains. Control is often difﬁcult. 
Dorsal horn afferent cells become sensitised when the pre-synaptic 
pain ﬁbre transmitter glutamate opens NMDA (N-methyl-D-Aspartate) 
channels on the post-synaptic cell, allowing calcium ions to enter them. 
Via the induction of nitric oxide these cells become more sensitive to 
the pre-synaptic signals. Blocking this pathway means either inhibit-
ing the NMDA channels, (Ketamine, possibly Dextromethorphan, 
methadone), or the calcium ion channel (anti convulsants, tricyclic anti 
depressants or SSRI’s, eg Venlafaxine). Gabapentin is the most widely 
used calcium channel inhibitor. Starting dose 100-300mg nightly 
increasing to 600mg every 8 hours or higher. There is no evidence base 
for combining more than one of each class of drug and the key practical 
point is probably to increase the dose of co-analgesics until either the 
pain is reduced or there are dose limiting side effects when another 
drug can used. Dexamethasone may reduce the perineural oedema 
when an expanding tumour is the cause. 
Metastatic Pain
Metastatic pain from bones needs a different approach If simple anal-
gesics are not working one-two fractions of palliative radiotherapy is 
usually adequate. Incident breakthrough pain is problematic. Bisphos-
phonates have been widely used in breast, prostate and myeloma, 
but the evidence base is less for lung cancer. They act by inhibiting 
osteoclast activation, reduce the release of inﬂammatory cytokines 
such as transforming growth factor B, thereby raising bone PH. Their 
effect is to preserve C and myelinated bone afferent ﬁbres. Options are 
Pamidronate 60-90mg IV every 3 weeks; oral Ibandronate (4mg IV for 
4 days) or Zolendronate orally. Pain reduction may be gradual - over 
days or even weeks. 
Non Pharmacological Management
In cancer, analgesics are likely to be less or ineffective unless they are 
used within a holistic strategy. Most patients are aware of a limited 
prognosis and are anxious, fearful and upset. They need time to discuss 
their personal feelings with a skilled professional. There should be a 
low threshold for anti depressant and anxiolytic treatment. Cognitive 
therapy is occasionally valuable. TENS is disappointing although it 
may give patients a sense of control. 
Referral
Patients with “difﬁcult to control” or morphine “poorly responsive” 
pain need to be referred early to a pain specialist. There is no easy deﬁ-
nition, but the author considers that 200mgs of morphine or equivalent 
per 24 hours is a possible threshold. Specialist advice may include the 
use of different co-analgesics, methadone (problematic because of long 
half life) and nerve blocks.
Nerve Blocks
Deﬁnitive blocks are usually preceded by trials with Lignocaine 20ml 
1-2% or Bupivacaine 20ml 0.5%. Intercostal blocks are carried out 
1-2 dermatomes above and below the affected one, and Lignocaine 
followed by permanent block with alcohol or phenol, radio frequency 
ablation or cryo-ablation. Pneumothorax is a complication. Similar 
treatment may be used for the brachial plexus. Intercostal block failure 
may need percutaneous rhizotomy (ie dorsal nerve root ablation) This 
is a highly specialised technique. Intrathecal epidural blocks are rarely 
used in lung cancer or mesothelioma, and spinal opioids are often 
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preferred because of severe neurological complications which occur in 
15-25%. 
In malignant mesothelioma, persistent resistant pain has been consid-
ered for percutaneous cordotomy, ie destruction of the contralateral 
spinothalamic tract in the neck. In 5 reports of 302 patients, pain relief 
was seen in 65%, respiratory depression in 0-4%, retention 6-10%, mir-
ror image pain 7-55%, and hemiparesis 0.4-9%. The opioid dose can be 
reduced thereby. A skilled team is essential. 
Adverse Events
Patients must be aware of these. Common errors are failure to prescribe 
early anti-emetics and bulk and stimulant laxatives when opioids are 
begun; to overlook the cholinergic side effects of tricyclics; the failure 
to decrease opioid doses in renal impairment; and the failure to use 
adequate opioids for fear of irrecoverable respiratory depression.
Prevention
Meticulous attention to analgesic management both intra and post 
operatively may reduce the incidence of post thoracotomy pain and 
accelerate recovery. Earlier palliative spine irradiation may postpone 
neurological problems and troublesome incident pain. 
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Comprehensive symptom management in advanced lung cancer
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Although we have entered the era of targeted therapy in lung cancer, 
the back bone of initial treatment for most patients with either non-
small cell (NSCLC) or small cell lung (SCLC) is myelotoxic chemo-
therapy. For patients receiving systemic treatment, platinum based 
regimens are used in the adjuvant setting, in combination with radiation 
for inoperable Stage III A/B and as primary therapy for advanced stage 
patients. While multiple different regimens have been developed and 
some alternative non-platinum based regimens are also used, all of 
these regimens have been developed with neutropenia as a limiting 
toxicity, which in fact has helped deﬁne the dose schedule of many of 
these regimens. Furthermore, these chemotherapy combinations were 
developed in younger, healthier patients, but are now applied world-
wide across a population of older patients with more co-morbid disease 
and therefore, more at risk for complications of treatment. Thus, both 
neutropenia and anemia are common sequallae of treatment that impact 
the quality of life and outcomes of patients being treated. While throm-
bocytopenia can also be an issue, it is not generally limiting except in 
patients with signiﬁcant bone marrow involvement , extensive prior 
chemotherapy and radiation and/or very advanced disease, particularly 
hepatic metastasis. While Interleukin 11 is available for treatment 
of patients with thrombocytopenia, its use has been limited. New 
thrombopoietic molecules have shown promising activity in immune 
thrombocytopenia and are just beginning to be studied as an adjunct to 
chemotherapy.
The risk of neutropenia and neutropenic complications varies sig-
niﬁcantly between patients with SCLC or NSCLC. In a prospective, 
nationwide registry in the United States, patients with SCLC receiving 
chemotherapy have nearly a 20% risk of developing febrile neutropenia 
at some point in their treatment course. At this level of risk, most pa-
tients with SCLC receiving standard platinum etoposide chemotherapy 
would be candidates for ﬁrst cycle proplylaxis with colony stimulating 
factors as established by NCCN guidelines and subsequently supported 
by the EORTC and ASCO expert panels. By contrast, patients with 
NSCLC have a substantially lower risk of developing febrile neutro-
penia with an overall rate of less than 5-10% in unselected populations 
receiving platinum based chemotherapy. The differences in risk may 
have to do with the briefer periods of neutropenia seen with taxanes 
or weekly vinorelbine or gemcitabine, used in NSCLC, compared to 
etoposide or irinotecan, more commonly used in SCLC. There are 
also overall differences between SCLC and NSCLC patients in terms 
of age, functional status, extent of disease, bone marrow involvement 
that may also be associated with poorer tolerance of myelosuppressive 
chemotherapy for the small cell population. 
SCLC was recognized as a rapidly fatal cancer and aggressive chemo-
therapy regimens were developed decades ago that led to signiﬁcant 
increase in survival, symptom improvement and quality of life beneﬁt. 
Studies of high dose chemotherapy have been largely unsuccessful in 
further improving outcomes, while the delivery of dose dense chemo-
therapy with the use of colony stimulating factors has provided modest 
improvement. However, reducing the dose of chemotherapy clearly led 
to reduced beneﬁt. With the availability of myeloid growth factors, neu-
tropenic complications can be minimized for the majority of patients 
and standard dose intensity maintained in the extensive stage patients. 
